NL-OMON28441招募中不适用
A phase I study of the combination of daily oral pazopanib with intravenous ifosfamide in patients with advanced solid malignancies.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 80
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects must provide written informed consent prior to performance of study
- •specific procedures or assessments, and must be willing to comply with treatment
- •and follow up assessments and procedures;
排除标准
- •1. Unable to discontinue prohibited medications, as listed in Section 5.5.2, 14 days or
- •five half-lives (whichever is longer) of the drug prior to Visit 1 and for the duration
- •of the study;
研究者
相似试验
招募中
不适用
A phase I study of the combination of daily oral pazopanib with intravenous docetaxel in patients with advanced solid malignancies.advanced solid malignanciescancerNL-OMON24614Erasmus University Medical Center72
已完成
不适用
A phase I study of the combination of daily oral SU11248 (Sunitinib) with intravenous ifosfamide in patients with advanced solid malignancies.NL-OMON30366Erasmus MC, Universitair Medisch Centrum Rotterdam72
已完成
1 期
Phase 1 study of once-daily and alternate-day oral administration of S-1 in patients with locally advanced or metastatic unresectable pancreatic cancer and recurrent pancreatic cancerlocally advanced or metastatic unresectable pancreatic cancer and recurrent pancreatic cancerJPRN-UMIN000006195Wakayama Medical University9
进行中（未招募）
不适用
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D insufficiency in the treatment of osteoporotic postmenopausal women and men. A prospective, international phase III study with a 6-month double-blind period to assess the efficacy and safety of a daily oral administration of S06911 versus S12911 (strontium ranelate 2g) and a 6-month open-labelled extension for a subgroup of patients to assess safety of a daily oral administration of S06911.EUCTR2009-013935-39-DKInstitut de Recherches Internationales Servier500
进行中（未招募）
1 期
The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D insufficiency in the treatment of osteoporotic postmenopausal women and men. A prospective, international phase III study with a 6-month double-blind period to assess the efficacy and safety of a daily oral administration of S06911 versus S12911 (strontium ranelate 2g) and a 6-month open-labelled extension for a subgroup of patients to assess safety of a daily oral administration of S06911.Osteoporotic men and osteoporotic postmenauposal womenMedDRA version: 12.0Level: LLTClassification code 10031283Term: Osteoporosis fractureMedDRA version: 12.0Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2009-013935-39-FRInstitut de Recherches Internationales Servier500